Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle length...
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
Proliferative Phase01:20

Proliferative Phase

The proliferative phase typically occurs after menstruation and lasts between 6 to 13 days in a standard 28-day cycle. This phase involves the reconstruction of the endometrium, guided by estrogen produced by the developing ovarian follicle.
Notably, the stratum basale, the basal layer of the endometrium, including the basal parts of the uterine glands, remains unaffected by menstruation. Stem cells in this layer undergo mitosis, regenerating the stratum functionalis and thickening the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protocol for the development of the WHO gestational weight gain charts.

BMJ open·2026
Same author

Readiness of University Students in Riyadh to Participate in Basic Life Support Programs: A Cross-Sectional Study.

Cureus·2024
Same author

Age and Gender-Specific Pattern of Cardiovascular Disease Risk Factors in Saudi Arabia: A Subgroup Analysis from the Heart Health Promotion Study.

Healthcare (Basel, Switzerland)·2023
Same author

The Impact of Age, Gender, Temporality, and Geographical Region on the Prevalence of Obesity and Overweight in Saudi Arabia: Scope of Evidence.

Healthcare (Basel, Switzerland)·2023
Same author

Preterm, early term, and post-term infants from Riyadh mother and baby multicenter cohort study: The cohort profile.

Frontiers in public health·2022
Same author

Independent Association of 25[OH]D Level on Reduced Glutathione and TNF-α in Patients ‎with Diabetes and/or Hypertension.

International journal of general medicine·2022

Related Experiment Video

Updated: May 26, 2026

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model
06:49

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model

Published on: April 7, 2023

Progestogen for treating threatened miscarriage.

Hayfaa A Wahabi1, Amel A Fayed, Samia A Esmaeil

  • 1Chair of Evidence-Based Healthcare and Knowledge Translation, King Saud University, Riyadh, Saudi Arabia, 11451.

The Cochrane Database of Systematic Reviews
|December 14, 2011
PubMed
Summary

Progestogen treatment effectively reduces the risk of miscarriage in women with threatened miscarriage. This therapy shows no increased adverse effects for mothers or newborns, though study limitations exist.

Related Experiment Videos

Last Updated: May 26, 2026

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model
06:49

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model

Published on: April 7, 2023

Area of Science:

  • Reproductive Medicine
  • Obstetrics
  • Pharmacology

Background:

  • Miscarriage is a common pregnancy complication.
  • Progesterone is crucial for uterine receptivity and pregnancy maintenance.
  • Inadequate progesterone is linked to miscarriage; supplementation is a potential treatment.

Purpose of the Study:

  • To evaluate the efficacy and safety of progestogens for treating threatened miscarriage.

Main Methods:

  • Searched Cochrane Pregnancy and Childbirth Group's Trials Register and bibliographies.
  • Included randomized or quasi-randomized controlled trials comparing progestogens to placebo, no treatment, or other interventions.
  • Assessed trial quality and extracted data; meta-analysis performed on four studies (421 participants).

Main Results:

  • Progestogen use showed a significant reduction in spontaneous miscarriage rates compared to placebo or no treatment (RR 0.53; 95% CI 0.35 to 0.79).
  • No increased rates of maternal antepartum hemorrhage or pregnancy-induced hypertension were observed.
  • Congenital abnormality rates in newborns were not significantly different between groups.

Conclusions:

  • Progestogens appear effective in treating threatened miscarriage without increasing maternal or neonatal adverse effects.
  • The meta-analysis was limited by a small number of studies and participants, and concerns regarding methodological quality.